Mucoactive preparations in the treatment of cough at arvi of the lower respiratory tract in children of early age: how to make a right decision
Abstract
The analysis of the world experience of using mucoactive drugs for cough of ukrainian, russian, english sources such as PubMed, Embase and Cochrane data-bases was carried out.
The article focuses on the features of the development of cough at ARVI of the lower respiratory tract in young children.
The results of experimental and clinical studies, confirming the complex nature of the action of mucoactive drugs ambroxol, carbocysteine, acetylcysteine (ACC), and revealing the mechanisms of their therapeutic efficacy at ARVI of the lower respiratory tract, are generalized.
The tactics of choosing mucoactive drugs have been substantiated, taking into account the effects of their main and accompanying actions. Practical recommendations for the use of mucoactive drugs are presented.
References
Averbukh VM, Lopatin AS. (2008). Postnazal'nyj sindrom. Consilium Medicum. 10 (10): 101—106.
Beketova GV, Goryacheva IP. (2017). Mukolitiki v pediatrii-novy`e grani izvestnogo. Pediatriya. Vostochnaya Evropa. 4: 683–696.
Braga PC, Allegra L, Rampoldi C, Ornaghi A, Beghi G. (1990). Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine lysine to patients with chronic bronchitis. Respiration. 57 (6): 353-358. https://doi.org/10.1159/000195871; PMid:2099568
Cazan D, Klimek L, Sperl A, Plomer M, Kolsch S. (2018). Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opinion on Drug Safety. 17 (12): 1211-1224. Epub 2018. Nov22. https://doi.org/10.1080/14740338.2018.1533954; PMid:30372367
Chalumeau M, Duijvestijn YC. (2013). Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database of Systematic Reviews: 5. https://doi.org/10.1002/14651858.CD003124.pub4; PMid:23728642
Chang AB et al. (2017). Management of children with chronic wet cough and protracted bacterial bronchitis: CHEST Guideline and Expert Panel Report. Chest. 151 (4): 884-890. https://doi.org/10.1016/j.chest.2017.01.025; PMid:28143696
Chernyavskli VI. (2013). Bakterial'nie bioplenki i infektsil. Annals of Mechnikov Institute. 1: 86–90.
Chistik T. (2014). Simptomaticheskoe lechenie suhogo kashlya pri vospalltel'nih i allergicheskih zabolevaniyah verhnih dihatel'nih. Novini meditsini ta farmatsii. 7–8 (449–500): 3–4.
Chuchalin AG. (2006). Institut pul'monologii: istoriya i osnovny'e nauchny'e napravleniya. Pul'monologiya. 4: 5–9.
Geppe NA, Snegotskaya MN, Nikitenko AA. (2007). Atsetiltsistein v lechenil kashlya u detei Pediatriya. Prilozhenie consilium medicum. 2: 43–47.
Geppe NA, Soroka ND, Simonova OI, Il'enkova NA, Karpovoj EP, Kovrigina ES, Malakhov AB. (2017). Terapiya kashlya u detej v ambulatornoj praktike. Obzor zasedaniya diskussionnogo kluba. Consilium Medicum. 19 (11): 47–55. doi: 1026442/2075-1753-19.11.4755.
Hooper C, Calvert J. (2008). The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 3 (4): 659. https://doi.org/10.2147/COPD.S3735
Kamaltinova EM. (2011). Mukolitiki v praktike pediatra (Mucolytics in pediatric practicel. Praktika pediatra (Elektronni resurs). URL: https://medi.ru/info/5573/.
Kardos P, Beeh KM, Sent U, Mueck T, Grater H, Michel MC. (2018). Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations. BMC Pharmacology and Toxicology. 19 (1): 40. https://doi.org/10.1186/s40360-018-0229-y; PMid:29973292 PMCid:PMC6030777
Kido H et al. (2007). Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Current pharmaceutical design. 13 (4): 405-414. https://doi.org/10.2174/138161207780162971; PMid:17311557
Klyachkina IL, Sinopal'nikov AI. (2018). Ambroksol v programme lecheniya khronicheskikh bronkholegochny'kh zabolevanij. Prakticheskaya pul'monologiya: 2.
Kosenko IM. (2013). Kashel' u detei - ratsional'nii podhod k lecheniyu. Voprosy sovremennoy pediatriii. 12 (1). 141-148. https://doi.org/10.15690/vsp.v12i1.571
Landini G, Di Maggio T, Sergio F, Docquier JD, Rossolini GM, Pallecchi L. (2016). Effect of high N-acetylcysteine concentrations on antibiotic activity against a large collection of respiratory pathogens. Antimicrobial agents and chemotherapy. 60 (12): 7513-7517. https://doi.org/10.1128/AAC.01334-16; PMid:27736757 PMCid:PMC5119039
Lee CS, Jang YY, Song JS, Song JH, Han ES. (2002). Ambroxol inhibits peroxynitrite-induced damage of α1-antiproteinase and free radical production in activated phagocytic cells. Pharmacology & toxicology. 91 (3): 140-149. https://doi.org/10.1034/j.1600-0773.2002.910309.x; PMid:12427115
Malerba M, Ragnoli B. (2008). Ambroxol in the 21st century: pharmaco- logical and clinical update. Expert opinion on drug metabolism & toxicology. 4 (8): 1119-1129. https://doi.org/10.1517/17425255.4.8.1119; PMid:18680446
Mescheryakova NN, Belevskii AS. (2016). Lechenie kashlya za predelami klinicheskih rekomendatsii. Astma i allergiya. 4: 21–24.
Okhotnikova EN. (2016). Sovremenny'e vozmozhnosti kompleksnogo vozdejstviya mukoaktivnoj terapii bronkhoobstruktivnogo sindroma u detej. Sovremennaya pediatriya. 2: 78–83.
Paleari D, Rossi GA, Nicolini G, Olivieri D. (2011). Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert opinion on drug discovery. 6 (11): 1203–1214. https://doi.org/10.1517/17460441.2011.629646; PMid:22646987.
Protsyuk RG, Vlasova GI. (2014). Milliarniy tuberkulez u detey i vzroslih (klinicheskaya lektsiya). Pediatriya. Vostochnaya Evropa. 3 (07): 153–159.
Rechkina OO. (2019). Efekty' karbocysteyinu pry' hvorobax organiv dyhannya. Oglyad literatury'. Zdorov'ye dytyny. 14 (8): 66–72.
Scaglione F, Petrini O. (2019). Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive? Clinical Medicine Insights: Ear, Nose and Throat, 12, 1179550618821930. https://doi.org/10.1177/1179550618821930; PMid:30670922 PMCid:PMC6328955
Simonova OI. (2011). Osobennosti primeneniya mukolitikov pryamogo tipa deistviya v praktike pediatra. Voprosi sovremennoi pediatrii. 10 (1): 153-159.
Simonova OI. (2014). Mukolitiki dlya detei: slozhnie voprosi, vazhnie otveti. Voprosi sovremennoi pediatrii. 13 (1): 26-32. https://doi.org/10.15690/vsp.v13i1.909
Simonova OI. (2015). Prostie otveti na slozhnie voprosy o mukolitikah dlya detey (Simple answers to complex questions about mukolitiki for children). Voprosy sovremennoy pediatrii. 14 (4): 509-513. https://doi.org/10.15690/vsp.v14.i4.1391
Soldatova OV. (2015). E'ffektivnost' mukoaktivnoj terapii pri zabolevaniyakh organov dy'khaniya: Lazolvan® v lechenii kashlya u detej s rozhdeniya. Pediatriya. Vostochnaya Evropa. 3: 127-137.
Su X, Wang L, Song Y, Bai C. (2004). Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide. Intensive care medicine. 30 (1): 133-140. https://doi.org/10.1007/s00134-003-2001-y; PMid:14504727
Vysochina IL, Abaturov AE. (2019). Kashel' u detej: rasprostranennost' i znachenie v ambulatornoj praktike. Bezopasnost' molekuly' ambroksola kak osnova vy'bora lecheniya. Zdorov'e rebenka. 14 (7): 47-54.
Wang W, Zheng JP, Zhu SX, Guan WJ, Chen M, Zhong NS. (2015). Carbocisteine attenuates hydrogen peroxide-induced inflammatory injury in A549 cells via NF-κB and ERK1/2 MAPK pathways. International immunopharmacology. 24 (2): 306-313. https://doi.org/10.1016/j.intimp.2014.12.018; PMid:25533503
Yamaya M, Nishimura H, Shinya K, Hatachi Y, Sasaki T, Yasuda H, Deng X. (2010). Inhibitory effects of carbocisteine on type A seasonal influenza virus infection in human airway epithelial cells. American Journal of Physiology-Lung Cellular and Molecular Physiology. 299 (2): L160-L168. https://doi.org/10.1152/ajplung.00376.2009; PMid:20543005
Yamaya M, Nomura K, Arakawa K, Nishimura H, Lusamba Kalonji N, Kubo H, Kawase T. (2016). Increased rhinovirus replication in nasal mucosa cells in allergic subjects is associated with increased ICAM-1 levels and endosomal acidification and is inhibited by L-carbocisteine. Immunity, Inflammation and Disease. 4 (2): 166-181. https://doi.org/10.1002/iid3.102; PMid:27957326 PMCid:PMC4879463
Yang B et al. (2002). Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. European Respiratory Journal. 19 (5): 952-958. https://doi.org/10.1183/09031936.02.00253302; PMid:12030738
Zaitseva OV. (2015). Osobennosti terapi kashlya u detel. Voprosi prakticheskoj pediatrii. 10 (10): 68–74.
Zy'kov KA, Agapova OYu, Sokolov EI. (2014). Novy'e vozmozhnosti primeneniya ambroksola v pul'monologii: vliyanie na bioplenki. Bolezni organov dy'khaniya. Prilozhenie k zhurnalu Consilium Medicum. 1: 27–32.
Downloads
Published
Issue
Section
License
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
